Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06306963Recruiting

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Role: collaborator

NCT06004596Not ApplicableCompleted

Establishing a Pediatric Reference Range for the 13C-Spirulina Gastric Emptying Breath Test (GEBT)

Role: lead

NCT04772261Not ApplicableCompleted

GEBT Lot-to-Lot and Biological Variability

Role: lead

NCT04684992Not ApplicableCompleted

GEBT Telehealth Administration Usability Study

Role: lead

NCT04635306Not ApplicableTerminated

13C-Spirulina Nitrogen Content GEBT Study

Role: lead

NCT04607304Not ApplicableCompleted

ABCA2 GIRMS Analytical Validation Clinical Performance Study

Role: lead

All 6 trials loaded